PAINWeek 2018

Dr Zacharoff offered several tips to PAINWeek attendees to help improve their communication with patients.

A clinical pathway designed to reduce variations in opioid prescriptions for acute pain in children discharged after orthopedic surgery, was found to be effective in reducing prescriptions while maintaining analgesia.

DFN-11, a 3 mg subcutaneous (SC) sumatriptan autoinjector, may provide an alternative to SC sumatriptan 6 mg for individuals with episodic migraine, as it was found to have a lower incidence of side effects and injection site reactions.

Perioperative and emergency department use of non-steroidal anti-inflammatory drugs as part of a multimodal analgesia regimen may improve pain control in pediatric populations and avoid opioid-related adverse events.

Dr Prasad highlights the importance of interdisciplinary approaches to the management of chronic pain.

Oxycodone ARIR (RoxyBondTM), a novel abuse-deterrent formulation of immediate-release oxycodone, may have comparable safety and efficacy to IR oxycodone.

A single dose of ibuprofen was superior to acetaminophen plus codeine for reducing pain 6 hours after a third molar extraction.

Dr Argoff presented an overview of diagnostic tests and available treatments for small-fiber polyneuropathies.

Fremanezumab may be efficacious for the prophylaxis of chronic migraine in individuals with comorbid migraine and moderate/moderate to severe depression.